Bristol Myers Squibb™

Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases

First presentation of data from the Phase 3 TRANSFORM study of CD19-directed CAR T cell therapy Breyanzi (lisocabtagene maraleucel) in second-line relapsed or refractory (R/R) large B-cell lymphoma

Research from industry-leading multiple myeloma program with new analyses for the first-in-class anti-BCMA CAR T cell therapy, Abecma (idecabtagene vicleucel), as well as studies in heavily-treated disease highlighting CELMoD®s, with new safety and efficacy results for iberdomide and first presentation of combination data with CC-92480

First clinical results for anti-SIRPa antibody CC-95251 and CELMoD® CC-99282 in patients with R/R non-Hodgkin's lymphoma showcasing pipeline potential through multiple modalities

(PRINCETON, N.J., November 4, 2021) -- Bristol Myers Squibb (NYSE: BMY) today announced the presentation of research across a wide range of hematologic diseases at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, which will take place in Atlanta, Georgia, and virtually, from December 11 to 14, 2021. Data from more than 80 company-sponsored studies will be featured, including 23 oral presentations, highlighting key research and development programs in lymphomas, leukemias, multiple myeloma and myeloid diseases, and showcasing our commitment to delivering transformative medicines across major hematologic diseases.

Key data being presented by Bristol Myers Squibb and its partners at the 2021 ASH Annual Meeting and Exposition include:

- First presentation of results from pivotal Phase 3 TRANSFORM study evaluating CD19-directed chimeric antigen receptor (CAR) T cell therapy *Breyanzi* (lisocabtagene maraleucel) head-to-head against the current standard of care

treatment approach for second-line relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

- Two-year follow-up data from the pivotal TRANSCEND NHL 001 study of *Breyanzi* in third-line and later R/R LBCL
- First clinical results for anti-SIRPα antibody CC-95251 plus rituximab, as well as first clinical results for CELMoD® CC-99282, both in patients with R/R non-Hodgkin's lymphoma
- First disclosure of safety and efficacy results from dose expansion of the MM-001 study evaluating CELMoD® iberdomide in combination with dexamethasone in patients with R/R multiple myeloma
- First disclosure of preliminary results from the Phase 1/2 MM-002 study of CELMoD® CC-92480 in combination with dexamethasone and bortezomib in patients with R/R multiple myeloma
- Further analyses from the pivotal KarMMa trial in R/R multiple myeloma evaluated baseline predictors of complete responses and outcomes for patients treated with subsequent anti-myeloma therapies, including alternative B-cell maturation antigen (BCMA)-directed therapies, after treatment with *Abecma* (idecabtagene vicleucel),the first-in-class BCMA-directed CAR T cell therapy
- Abstracts highlighting multiple Bristol Myers Squibb's therapies in hard-to-treat myeloid diseases, including longer-term data and analyses of different acute myeloid leukemia subtypes and baseline characteristics with *Onureg*® (azacitidine tablets) from the Phase 3 QUAZAR® AML-001 study and safety with *Inrebic*® (fedratinib) from the Phase 3b FREEDOM trial in myelofibrosis
- Updated analyses of *Reblozyl*® (luspatercept-aamt) from the Phase 2 BEYOND study in beta thalassemia and from the Phase 3 MEDALIST study in lower-risk myelodysplastic syndromes

Selected Bristol Myers Squibb studies at the 63rd ASH Annual Meeting and Exposition include:

Abstract Title	Author	Presentation Type/#	Session Title	Session Date/Time
Acute Myeloid Leukemia				
Prognostic Impact of NPM1 and FLT3 Mutations at Diagnosis and Presence of Measurable Residual Disease (MRD) after Intensive Chemotherapy (IC) for Patients with Acute Myeloid Leukemia (AML) in Remission: Outcomes from the QUAZAR AML-001 Trial of Oral Azacitidine (Oral-AZA) Maintenance	Hartmut Döhner	Oral Abstract #804	617. Acute Myeloid Leukemia: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: New options of risk assessment and prediction of therapy response in AML	Monday, December 13, 5:45 PM
Long-term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial	Andrew Wei	Oral Abstract #871	615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: Updates in treatment for high-risk AML	Monday, December 13, 6:15 PM
Beta Thalassemia				
Luspatercept Redistributes Body Iron to the Liver in Transfusion-Dependent-Thalassemia (TDT) During Erythropoietic Response	Maciej Garbowski	Oral Abstract #761	102. Iron Homeostasis and Biology: Disorders of Iron and Heme and Novel Treatments	Monday, December 13, 5:30 PM
Luspatercept Improves Health-Related Quality of Life (HRQoL) Symptoms and RBC Transfusion Burden in	Antonis Kattamis	Poster Abstract #3081	112. Thalassemia and Globin Gene Regulation: Poster III	Monday, December 13, 6:00 - 8:00 PM

Patients with Non-Transfusion-Dependent ß-thalassemia (NTDT) in the BEYOND Trial				
Graft vs. Host Disease				
Overall Survival of Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate After Allogeneic Hematopoietic Stem Cell Transplantation - Analysis of the Center for International Blood and Marrow Transplant Research Database	Leslie Kean	Poster Abstract #3912	722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster III	Monday, December 13, 6:00 – 8:00 PM
Lymphoma				
Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed by Autologous Stem Cell Transplantation (ASCT) as Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Randomized Phase 3 TRANSFORM Study	Manali Kamdar	Oral Abstract #91	704. Cellular Immunotherapies: Cellular Therapies for Lymphomas	Saturday, December 11, 9:30 AM
Ruxolitinib Plus Nivolumab in Patients with R/R Hodgkin Lymphoma after Failure of Check-Point Inhibitors: Preliminary	Veronika Bachanova	Oral Abstract #230	624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials Hematology Disease Topics & Pathways:	Saturday, December 11, 2:15 PM

Report on Safety and Efficacy			Clinical Trials	
Nivolumab First-Line Therapy for Elderly Hodgkin Lymphoma Patients: a LYSA Phase II Study	Julien Lazarovici	Oral Abstract #232	624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Trials	Saturday, December 11, 2:45 PM
OUTREACH: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered as Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)	John Godwin	Poster Abstract #1762	704. Cellular Immunotherapies: Clinical: Poster I	Saturday, December 11, 5:30 – 7:30 PM
Six-Year Results from the Phase 3 Randomized Study Relevance Show Similar Outcomes for Previously Untreated Follicular Lymphoma Patients Receiving Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed By Rituximab Maintenance	Franck Morschhauser	Poster Abstract #2417	623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II	Sunday, December 12, 6:00 - 8:00 PM
Differential Effects of Iberdomide Versus Revlimid on Leukocyte Trafficking, Immune Activation and DLBCL Tumor Cell Killing	Yumi Nakayama	Oral Abstract #718	622. Lymphomas: Translational-Non-Genetic: Lymphoma biology	Monday, December 13, 3:30 PM
Completed Induction Phase Analysis of MAGNIFY: Phase 3b Study of Lenalidomide + Rituximab (R2) Followed By	Frederick Lansigan	Oral Abstract #812	623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Follicular Lymphoma:	Monday, December 13, 4:45 PM

Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma			Advances in Treatment Approaches	
Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPa Antibody that Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells when Combined with Rituximab	Henry Chan	Poster Abstract #2271	605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster II	Monday, December 13, 6:00 - 8:00 PM
Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-term Response in Lisocabtagene Maraleucel (liso-cel)–Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)	Jerill Thorpe	Poster Abstract #2417	704. Cellular Immunotherapies: Clinical: Poster III	Monday, December 13, 6:00 - 8:00 PM
Two-Year Follow-up of TRANSCEND NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)	Jeremy Abramson	Poster Abstract #2840	704. Cellular Immunotherapies: Clinical: Poster III	Monday, December 13, 6:00 - 8:00 PM
Cost-effectiveness of Liso-cel versus Axi-cel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma	Christopher Parker	Poster Abstract #3003	902. Health Services Research—Lymphoid Malignancies: Poster II	Monday, December 13, 6:00 - 8:00 PM
Clinical Activity of CC-99282, a Novel, Oral Small Molecule	Jean-Marie Michot	Poster Abstract #3574	626. Aggressive Lymphomas: Prospective	Monday, December 13, 6:00 - 8:00 PM

Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients (Pts) with Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) – First Results from a Phase 1, Open-Label Study			Therapeutic Trials: Poster III	
Multiple Myeloma				
Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Dose-Expansion Phase of the CC-220-MM-001 Trial	Sagar Lonial	Oral Abstract #162	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Novel Targets and Amyloid	Saturday, December 11, 1:15 PM
Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the CONNECT® Multiple Myeloma (MM) Disease Registry	Sundar Jagannath	Oral Abstract #117	905. Outcomes Research- Lymphoid Malignancies: Multiple Myeloma and Other Plasma Cell Disorders	Saturday, December 11, 10:00 AM
Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial	Nina Shah	Poster Abstract #1739	704. Cellular Immunotherapies: Clinical: Poster I	Saturday, December 11 5:30 - 7:30 PM
Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and	Paula Rodriguez-Otero	Poster Abstract #1978	905. Outcomes Research—Lymphoid Malignancies: Poster I	Saturday, December 11, 5:30 – 7:30 PM

Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) vs. Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up				
Updated Clinical and Correlative Results From the Phase I CRB-402 Study of the BCMA-Targeted CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma	Noopur Raje	Oral Abstract #548	Cellular Immunotherapies: Cellular Therapies for Myeloma	Sunday, December 12 4:45 PM
CC-92480, a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD) Agent, in Combination with Dexamethasone (DEX) and Bortezomib (BORT) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Phase 1/2 Study CC-92480-MM-002	Paul Richardson	Poster Abstract #2731	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	Sunday, December 12 6:00 - 8:00 PM
Subsequent Anti-myeloma Therapy after Idecabtagene Vicleucel (Ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study	Paula Rodriguez-Otero	Poster Abstract #2743	653. Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster II	Sunday, December 12 6:00 – 8:00 PM

Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (ide-cel, bb2121)	Michel Delforge	Poster Abstract #2835	704. Cellular Immunotherapies: Clinical: Poster II	Sunday, December 12, 6:00 – 8:00 PM
Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6–24) for Patients with Relapsed and Refractory Multiple Myeloma in the KarMMa Clinical Trial	Nina Shah	Poster Abstract #3041	Session Name: 905. Outcomes Research—Lymphoid Malignancies: Poster II	Sunday, December 12 6:00 – 8:00 PM
Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients	Oliver Van Oekelen	Oral Abstract #730	651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: The Myeloma Immune Microenvironment	Monday, December 13, 3:30 PM
Myelodysplastic Syndrome				
Treatment Duration and Exposure Adjusted Safety Analysis in the MEDALIST Study (luspatercept)	Uwe Platzbecker	Poster Abstract #1524	637. Myelodysplastic Syndromes — Clinical and Epidemiological: Poster I	Saturday, December 11 5:30 - 7:30 PM
Myelofibrosis				

Safety and Tolerability of Fedratinib, an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-risk Myelofibrosis (MF) Previously Treated with Ruxolitinib: Results from the Phase 3b FREEDOM Trial	Vikas Gupta	Oral Abstract #389	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Novel Therapies for MPNs and JAK inhibitors for Myelofibrosis	Sunday, December 12, 10:30 AM
Spleen and Symptom Responses with Fedratinib (FEDR) Patients with Myelofibrosis (MF) and Substantial Splenomegaly	Jean-Jacques Kiladjian	Poster Abstract #2576	634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster II	Sunday, December 12 6:00 - 8:00 PM

###

Bristol Myers Squibb: Creating a Better Future for Cancer Patients

Bristol Myers Squibb is inspired by a single vision — transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.

ABECMA – EU Indication

Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

For more information about Abecma: www.fass.se

ONUREG – EU Indication

Onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (HSCT)

For more information about Onureg: www.fass.se

REBLOZYL – EU Indication

Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy.
Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia.

For more information about Reblozyl: www.fass.se

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb company and Juno Therapeutics, a Bristol-Myers Squibb company.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that future study results will be consistent with the results to date, that the product candidates, treatments and combination treatments described in this release may not receive regulatory approval for the indications described in this release, any marketing approvals, if granted, may have significant limitations on their use, and, if approved, whether such product candidates, treatments or combination treatments for such indications described in this release will be commercially successful. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2020, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

# # #

Contact:
Bristol Myers Squibb Sweden, Media Inquiries

Anna Johansson, Senior Manager Corporate Affairs, Bristol Myers Squibb Sverige,
anna.johansson@bms.com, 0702-08 17 86.